Video-oculography / Neuropsycholog… for Parkinson's (NCT04731246)
Eye movements predict thinking decline
- Trial ID
- NCT04731246
- Official Title
- Video-oculography and Parkinson's Disease: A Prospective Study
- Goal
- Eye movements predict thinking decline
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Association de Recherche Bibliographique pour les Neurosciences
- Study Type
- INTERVENTIONAL
- Enrollment
- 30 participants
- Conditions
- Parkinson Disease, Idiopathic
- Interventions
- Video-oculography / Neuropsychological evaluations
Summary For Families
It aims to track how eye-movement signs change over seven years in people with mild to moderate Parkinson's, and whether those eye signs match changes in movement, non-movement symptoms, and thinking skills, plus how Parkinson's medicines affect those eye-movement measures. The team uses video-oculography, a camera-based test that records eye movements, together with neurologic and cognitive evaluations to follow patients over time. They are looking for adults 18 and older with clinically defined Parkinson's at stage 1 to 3, routine brain imaging that supports the diagnosis, normal or only mild thinking problems, a normal clinical eye exam (small tracking problems allowed), and a caregiver.
Locations
- Centre Mémoire / Centre de Gérontologie Clinique Rainier III / Princess Grace Hospital, Monaco, Monaco
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Video-oculography / Neuropsychological evaluations. It aims to track how eye-movement signs change over seven years in people with mild to moderate Parkinson's, and whether those eye signs match changes in movement, non-movement symptoms, and thinking skills, plus how Parkinson's medicines affect those eye-movement measures. The team uses video-oculography, a camera-based test that records eye movements, together with neurologic and cognitive evaluations to follow patients over time. They are looking for adults 18 and older with clinically defined Parkinson's at stage 1 to 3, routine brain imaging that supports the diagnosis, normal or only mild thinking problems, a normal clinical eye exam (small tracking problems allowed), and a caregiver.
- Who can participate?
- Participants must be at least 18 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- You are never charged a fee to join a legitimate clinical trial, and the study treatment and study-specific tests are provided by the trial sponsor at no charge. In the US, routine care you would receive anyway can still be billed to you or your insurance; coverage rules differ by country, and trials in the UK and Canada usually run through public health systems. Travel, parking, and time are real costs, and some trials reimburse them while others do not. Before enrolling, ask the study coordinator to explain in writing what is and is not covered.
- How long does the trial last?
- This trial is estimated to last approximately 10 years and 6 months.
- Can I leave the trial if I change my mind?
- Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
- Can my spouse or care partner come with me to visits?
- In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.
- Will I get a placebo in this trial?
- Everyone in this trial receives the experimental treatment. There is no placebo group.
- How many visits does this trial involve?
- Participants will be followed for a total of 7 years.
- What procedures are involved in this trial?
- Based on the protocol, this trial involves: Thinking & memory tests (non-invasive). Confirm the full schedule with the study coordinator.